## Jason R Dobson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3499594/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944.	13.5	1,242
2	Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47, 106-114.	9.4	830
3	Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature, 2016, 535, 148-152.	13.7	674
4	A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research, 2016, 22, 5696-5705.	3.2	245
5	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Medicine, 2014, 6, 5.	3.6	186
6	Runx2 Transcriptional Activation of Indian Hedgehog and a Downstream Bone Metastatic Pathway in Breast Cancer Cells. Cancer Research, 2008, 68, 7795-7802.	0.4	160
7	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441.	3.2	134
8	Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis. Genome Biology, 2014, 15, R52.	13.9	122
9	Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. Molecular Cancer Research, 2017, 15, 1722-1732.	1.5	119
10	Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours. British Journal of Cancer, 2021, 125, 28-37.	2.9	62
11	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 2015, 230, 2683-2694.	2.0	58
12	Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Research, 2010, 12, R89.	2.2	56
13	Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition. Oncotarget, 2017, 8, 17610-17627.	0.8	53
14	The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation. Oncotarget, 2016, 7, 38270-38281.	0.8	51
15	Expansion of GA Dinucleotide Repeats Increases the Density of CLAMP Binding Sites on the X-Chromosome to Promote Drosophila Dosage Compensation. PLoS Genetics, 2016, 12, e1006120.	1.5	48
16	hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell International, 2014, 14, 73.	1.8	46
17	Transcriptional corepressor TLE1 functions with Runx2 in epigenetic repression of ribosomal RNA genes. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4165-4169.	3.3	41
18	A Runx2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation. Journal of Cell Science, 2012, 125, 2732-9.	1.2	36

#	Article	IF	CITATIONS
19	The bone-specific Runx2-P1 promoter displays conserved three-dimensional chromatin structure with the syntenic Supt3h promoter. Nucleic Acids Research, 2014, 42, 10360-10372.	6.5	28
20	Expression of the ILâ€11 Gene in Metastatic Cells Is Supported by Runx2â€Smad and Runx2â€cJun Complexes Induced by TGFβ1. Journal of Cellular Biochemistry, 2015, 116, 2098-2108.	1.2	21
21	Identifying Nuclear Matrixâ€Attached DNA Across the Genome. Journal of Cellular Physiology, 2017, 232, 1295-1305.	2.0	19